Analisis Efektivitas Biaya Pengobatan Pasien Tuberkulosis Paru Di RSUD Banyumas Tahun 2022
DOI:
https://doi.org/10.61132/prosemnasikk.v1i1.13Keywords:
Cost Effectiveness Analysis, ACER, Pulmonary TBAbstract
Pulmonary tuberculosis is caused by Mycobacterium tuberculosis and typically affects the lungs. Tuberculosis is a highly significant global health issue, especially in developing countries like Indonesia, where it is a leading cause of death and has the highest morbidity rates. The purpose of this study is to evaluate the cost-effectiveness of treating pulmonary tuberculosis patients at RSUD Banyumas in 2022. The research method employed is descriptive research with retrospective data collection. This study utilizes Cost Effectiveness Analysis (CEA), which is a form of economic evaluation that compares the cost-effectiveness ratios of various alternative treatment interventions or programs. The research findings indicate that the more cost-effective therapy for pulmonary tuberculosis treatment at RSUD Banyumas in 2022 is the use of OAT Kombipak, with an Average Cost-Effectiveness Ratio (ACER) of Rp. 196,014.00. This is more cost-efficient compared to OAT KDT therapy, which has an ACER of Rp. 204,551.00. Therefore, based on this research, the Kombipak OAT therapy is considered more cost-effective due to its lower ACER value.
Downloads
References
Andayani, Tri M 2013, Farmakoekonomi Prinsip dan Metodologi, Yogyakarta, Bursa Ilmu.
Bootman,J, L., dkk 2005, Principles Of Pharmacoeconomics, Harvey Whitney Books Company.
Damayati, DS, dkk 2018, ‘Risiko Kejadian TB Paru di Wilayah Kerja Puskesmas Liukang Tupabbiring Kabupaten Pangkep’, Higiene, vol.4, no.2, hh. 121-130, dilihat 23 Oktober 2022, https://journal.uin-alauddin.ac.id/index.php/higiene/article/view/5859
Dande, P & Samant, P 2018, ‘Acquaintance to Artificial Neural Networks and use of artificial intelligence as a diagnostic tool for tuberculosis: A review’, Elsevier, vol.108, hh. 1-9, dilihat 23 Oktober 2022, https://doi.org/10.1016/j.tube.2017.09.006
Iswari, A dkk 2020, ‘Analisis Biaya Penyakit Tuberkulosis Studi Kasus di Salah Satu Puskesmas dan Rumah Sakit di Yogyakarta’, Majalah Farmaseutik, vol. 16, no.2, hh. 211-217, dilihat 23 Oktober 2022, https://jurnal.ugm.ac.id/majalahfarmaseutik/article/view/54172
Kemenkes RI 2018, Tuberkulosis Kementerian Kesehatan Republik Indonesia, Pusat Data dan Informasi, Jakarta, Rasuna Said.
Kemenkes RI 2019, Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis, Jakarta, Kemenkes RI. Diakses dari : https://yankes.kemkes.go.id/unduhan/fileunduhan_1610422577_801904.pdf
Kumar, S & Baldi, A 2013, ‘Pharmacoeconomics: Principles, Methods and Economic Evaluation of Drug Therapies’, PhTechMed, vol.2, no.5, hal. 362-369, dilihat 23 Oktober 2022, publication at: https://www.researchgate.net/publication/258959294
Mangngi, MP 2019, Faktor Risiko Umur, Jenis Kelamin dan Kepadatan Hunian Terhadap Kejadian TB Paru di Puskesmas Naibonat Tahun 2018, KTI, diterbitkan 19 Juni 2019. Diakses 8 Agustus 2023: http://repository.poltekeskupang.ac.id/1936/1/mychel_pili_mangngi_KTI.pdf
Melia, F dan Eyis H 2019, Faktor Risiko Kejadian Tuberculosis, Jurnal Kesehatan, vol.10, no.3, hh. 252-260. Diakses 8 Agustus 2023: http://ejurnal.stikesprimanusantara.ac.id/index.php/JKPN/article/download/792/pdf Profil Kesehatan Jawa Tengah 2021, Dinas Kesehatan Jawa Tengah, Jawa Tengah.
RSUD Banyumas, Video Profil RSUD Banyumas, 19 Oktober 2021. https://www.rsudbanyumas.my.id/2021/10/video-profil-rsud-banyumas-tahun-2021.html?m=1 diakses 22 Desember 2022
Ruru, R.I, dkk 2018, Analisis Efektivitas Biaya Pengobatan ISK Menggunakan Antibiotik Seftriakson dan Siprofloksasin di RSUP Prof.DR.R.D.X Manado, Pharmacon : ISSN:2302-2493.7(3):42-51. Daiakses 8 Agustu 2023, https://ejournal.unsrat.ac.id/v3/index.php/pharmacon/article/view/20238
Sabila, D 2016, Analisis Biaya Pengobatan Berdasarkan Clinical Pathway Tuberkulosis Paru di RSUD Sultan Syarif Mohamad Alkadrie Kota Pontianak, Media Neliti, dilihat 23 Oktober 2022, https://media.neliti.com/media/publications/192941-ID-analisis-biaya-pengobatan-berdasarkan-cl.pdf
Setiawan, D dkk 2017, Farmakoekonomi Modeling, Purwokerto, UMP Press.
Sinaga, AH & Astini, B 2022, ‘Analisis Efektivitas Biaya (CEA) Pengobatan Kombinasi dan OAT Pada Pasien Tuberkulosis Paru di Rumah Sakit Umum Imelda Pekerja Indonesia Medan’, JIFI (Jurnal Ilmiah Farmasi Imelda), vol.6, no.1, hh. 36-43, dilihat 23 Oktober 2022, https://jurnal.uimedan.ac.id/index.php/JURNALFARMASI/article/view/1113
Vogenberg, F.R. 2001, Introduction to applied pharmacoeconomics, The Mcgraw-Hill Companies, Inc., New York.
Wilthsire, CS, dkk 2018, ‘The Utility of Pharmacokinetik Studies Fox The Evaluation Of Exposure Respon Relationhips For Standard Dose anti tuerkulosis Drugs’, Elsevier, vol.108, hh.77-82, dilihat 23 Oktober 2022, DOI: 10.1016/j.tube.2017.11.004
World Health Organization (WHO) 2020, Global Tuberculosis Report 2020, Geneva, WHO.
Zulda, CD, dkk 2017, ‘Perbandingan Profil Penderita Tuberkulosis Paru Antara Perokok dan Non Perokok di Poliklinik Paru RSUP. Dr. M. Djamil Padang’, Jurnal Kesehatan Andalas, vol.6, no.1, hh. 123-127, dilihat 23 Oktober 2022, http://jurnal.fk.unand.ac.id/index.php/jka/article/vii
